为评价重组禽流感病毒（H5+H7）三价灭活疫苗（H5N1 Re-11株+Re-12株，H7N9 H7 Re-2株）免疫鸡群的临床应用效果及当前禽流感免疫程序的合理性，对河南省使用重组禽流感病毒（H5+H7）三价灭活疫苗免疫的940个存栏500只以上的养鸡场开展临床应用效果调查，并抽取328个场开展免疫抗体检测。结果显示：免疫后1周内出现不良反应的养鸡场190个，占20.21%（190/940）；发病的养鸡场140个，占14.89%（140/940）；出现死亡的养鸡场51个，占5.43%（51/940）。免疫后1周内出现不良反应的鸡只占0.11%，发病的占0.09%，死亡的占0.04%。血清样品的血凝（HA）和血凝抑制（HI）试验结果显示：H5亚型Re-11株场群合格率为97.56%，免疫抗体阳性率为94.20%；H5亚型Re-12株场群合格率为96.34%，免疫抗体阳性率为92.70%；H7亚型Re-2株场群合格率为98.17%，免疫抗体阳性率为94.67%。结果表明：重组禽流感病毒（H5+H7）三价灭活疫苗的鸡群免疫效果较好，免疫后的临床不良反应率极低。但在免疫过程中，应尽量消除影响疫苗临床效果的不利因素，定期开展免疫效果监测，及时调整免疫程序。本研究为全国高致病性禽流感疫苗的应用提供了参考。
In order to evaluate the clinical application effect of recombinant avian influenza virus（H5+H7）trivalent inactivated vaccines（H5N1 Re-11+Re-12 strain and H7N9 H7 Re-2 strain）in chickens and the rationality of current vaccination program，940 farms with more than 500 chickens were investigated in Henan Province，in which，328 farms were selected for detection of immune antibody. It was found that，within one week after vaccination，some adverse reactions revealed in 190 farms，accounting for 20.21%（190/940）；avian influenza outbreaks in 140 farms were detected，accounting for 14.89%（140/940）；and dead cases were found in 51 farms，accounting for 5.43%（51/940）. The proportions of chickens with adverse reactions，being infected and dead were 0.11%，0.09% and 0.04%，respectively. It was found that，by hemagglutination（HA）and hemagglutination inhibition（HI）test for serum samples，the farm/flock qualified rates of H5 Re-11，H5 Re-12 and H7 Re-2 strain were 97.56%，96.34% and 98.17%，respectively，and their positive rates of immune antibodies were 94.20%，92.70% and 94.67%，respectively. It was concluded that the recombinant avian influenza virus（H5+H7）trivalent inactivated vaccine could receive good effect in chickens，with lower level of adverse reaction. However，any adverse factors therefrom should be eliminated to the greatest extent during the process of vaccination，which should be monitored regularly，and the vaccination program should also be timely adjusted. Some references were provided for the application of vaccines against highly pathogenic avian influenza virus in China.